CB1 and CB2 are the two main cannabinoid receptors in the human body, and they divide up responsibilities in a surprisingly clean way: CB1 dominates in the brain and nervous system, while CB2 is concentrated in immune cells and tissues. Together, they help regulate pain, inflammation, appetite, mood, gut motility, bone turnover, and more. The split is not absolute, though, and research over the past two decades has found both receptors in places nobody initially expected, complicating the tidy “brain receptor vs. immune receptor” story in ways that matter for drug development and human health.
Where Each Receptor Lives
CB1 is one of the most abundant receptors in the brain. It sits on neurons throughout the cortex, hippocampus, basal ganglia, and cerebellum, which is why activating it affects memory, movement, and perception. But CB1 is not exclusively a brain receptor. It also shows up at lower levels in the heart, lungs, adrenal glands, reproductive organs, liver, fat tissue, muscle, and pancreas.1PubMed. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations That peripheral presence turns out to be critical for understanding how the endocannabinoid system shapes metabolism and energy balance.
CB2, by contrast, was originally thought to be absent from the brain entirely. Its heaviest expression is in immune tissues: the spleen, tonsils, and bone marrow. Among circulating blood cells, B cells carry the most CB2, followed by natural killer cells, then monocytes, with T cells bringing up the rear.1PubMed. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations In immune tissue, CB2 expression can reach levels comparable to what CB1 achieves in the brain. Researchers have since found CB2 on microglia, the brain’s resident immune cells, which has opened an entire line of inquiry into neuroinflammation.2PubMed Central. CB2 Receptor in Microglia: The Guardian of Self-Control
Both receptors also appear in human skin, and in a pattern that caught researchers off guard. CB1 and CB2 show up on nerve fiber bundles, mast cells, macrophages, keratinocytes in the outer skin layer, hair follicles, oil-producing sebaceous glands, and sweat glands. Within structures like hair follicles and sebaceous glands, the two receptors distribute in complementary patterns, suggesting they coordinate rather than duplicate each other’s work.3PubMed. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin
How They Signal Inside Cells
Both CB1 and CB2 belong to a large family of receptors that work by coupling to proteins inside the cell called G proteins. When an endocannabinoid or another molecule binds to either receptor, the G protein splits into subunits that go on to flip various cellular switches. The most consistent effect is a slowdown in the production of a signaling molecule called cyclic AMP, which dials down the cell’s activity.4PubMed. Cannabinoid receptor signaling Activating these receptors also triggers pathways that influence gene expression, calcium flow, and potassium channels, which is why the downstream effects are so varied depending on the tissue.5PubMed Central. Cannabinoid CB1 and CB2 Receptor Signaling and Bias
In the brain, one of CB1’s most distinctive jobs is retrograde signaling. When a receiving neuron gets too much stimulation, it releases endocannabinoids that travel backward across the synapse and bind to CB1 on the sending neuron, telling it to ease off. This “volume knob” function shapes both short-term and long-term changes in how strongly neurons communicate with each other, at both excitatory and inhibitory connections.6PubMed Central. Endocannabinoid signaling and synaptic function It is the reason cannabinoid signaling touches so many brain functions at once: anything that depends on fine-tuning synaptic strength, from learning to motor coordination, can be influenced.
Pain Processing
Pain was one of the first functions linked to cannabinoid receptors, and the picture that has emerged is that both CB1 and CB2 contribute, but through somewhat different channels. In animal models, activating either receptor reduces pain signaling in both acute and chronic settings.7Wiley Interdisciplinary Reviews: Membrane Transport and Signaling. Cannabinoid receptors and pain CB1 appears to be especially relevant for baseline pain sensitivity, the kind of sharp signal that tells you something hurts. CB2 becomes more important once inflammation enters the picture.
Experiments using selective blockers help tease the two apart. When researchers gave animals a compound that activates both receptors, blocking CB1 reversed the pain-relief effects in both ordinary nociceptive pain and inflammatory pain. Blocking CB2, on the other hand, only reversed the effects in the inflammatory condition.8PubMed. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain This distinction matters because drugs that avoid CB1 might still help with inflammatory pain without producing the psychoactive effects that come with stimulating brain CB1.
There is also evidence that hitting both receptors at once in the periphery produces additive benefits. In chronic inflammation models, locally administered CB1 and CB2 activators together reduced mechanical pain sensitivity more than either one alone.9PubMed Central. Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis That additive effect hints at why whole-plant cannabinoid preparations, which hit multiple targets simultaneously, sometimes perform differently from single-molecule drugs in patient reports.
Immune Regulation and Inflammation
CB2’s role in the immune system goes well beyond being present on immune cells. When researchers delete the CB2 gene in mice, the animals develop exaggerated inflammatory responses across multiple disease models. Their immune cells become overactive, suggesting that CB2 normally acts as a brake on inflammation.10PubMed Central. The CB 2 receptor and its role as a regulator of inflammation Activating CB2 with cannabinoid compounds generally dials down immune cell activation, and administering CB2-targeted drugs in animal models of inflammatory disease can slow disease progression.
This immune-calming function has attracted interest in neurological conditions where the brain’s own immune cells, microglia, become chronically overactivated. Because CB2 sits on microglia and its activation reduces neuroinflammation without producing psychoactive effects, it has become an appealing target for research into neurodegenerative diseases.2PubMed Central. CB2 Receptor in Microglia: The Guardian of Self-Control The broader idea is that CB2 helps maintain what researchers describe as a homeostatic immune balance: not too much response, not too little.11PubMed Central. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation
Appetite, Metabolism, and Weight
The “munchies” are perhaps the most culturally familiar effect of cannabinoid receptor activation, and CB1 is the receptor responsible. In the brain, CB1 modulates food intake and the motivation to eat palatable food. But the metabolic story extends far beyond appetite. CB1 receptors in the liver, fat tissue, muscle, and pancreas also participate in regulating how the body handles fats and sugars.12PubMed. CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health
In obesity, the endocannabinoid system appears to become chronically overactive. Endocannabinoid levels rise in both central and peripheral tissues, and CB1 is upregulated.13PubMed Central. The endocannabinoid system in appetite regulation and treatment of obesity This creates a feedback loop: more CB1 activation promotes fat storage and increases appetite, which in turn keeps endocannabinoid levels high. Disruption of normal endocannabinoid tone has been linked to dyslipidemia, glucose intolerance, and the cluster of problems grouped under metabolic syndrome.14Journal of Pharmaceutical Research. Peripherally Selective CB1 Receptor Antagonists: A Promising Therapeutic Strategy for Metabolic Disorders
This is where the story took a dramatic turn in drug development, but the pharmacology is covered later in the article.
The Gut Connection
Both CB1 and CB2 are expressed throughout the gastrointestinal tract, where they help regulate the speed at which food moves through and how permeable the intestinal lining is to various molecules. Endocannabinoids affect gut motility in a receptor-specific way, and cannabinoids also appear to reduce intestinal inflammation by lowering inflammatory enzyme activity and adjusting cytokine levels.15PubMed Central. Effects of Cannabinoids on Intestinal Motility, Barrier Permeability, and Therapeutic Potential in Gastrointestinal Diseases
In human studies, dronabinol, a synthetic compound that activates both cannabinoid receptors, delayed stomach emptying of solid food and dampened the wave-like contractions of the colon that normally follow a meal.16Clinical Gastroenterology and Hepatology. CB1 and CB2 Receptors: Functions in the Body That slowing effect is consistent with the constipation commonly reported by frequent cannabis users, and it is also the reason cannabinoid-based therapies have been explored for conditions involving overactive gut motility.
Heart and Blood Vessels
Endocannabinoids relax coronary arteries and decrease the heart’s workload, though under normal resting conditions they do not appear to be major regulators of blood pressure or heart rate. Their cardiovascular role is more like a stress-response system that kicks in during emergencies. During a heart attack, for example, endocannabinoid levels rise, and the evidence suggests they are largely protective: they reduce tissue damage and arrhythmias.17PubMed Central. Endocannabinoids and the heart CB2 stimulation appears to slow the progression of atherosclerosis in animal models, adding another dimension to its anti-inflammatory profile. Mice that have been engineered to have higher endocannabinoid levels show less age-related decline in heart function compared with normal mice.
CB1 activation can also lower blood pressure, which has prompted interest in the cannabinoid system as a potential avenue for managing hypertension.18PubMed. Cannabinoid-sensitive receptors in cardiac physiology and ischaemia However, this area remains early-stage, partly because stimulating CB1 broadly would produce too many central nervous system effects to be practical as a blood pressure treatment.
Bone Remodeling
Bone is constantly being built up and broken down by specialized cells, and cannabinoid receptors influence that balance. CB2 sits on osteoclasts, the cells that break down bone, and its role there is nuanced. In one line of research, blocking CB2 with an inverse agonist inhibited osteoclast formation and activity in the lab, while activating CB2 stimulated osteoclast formation.19Endocrinology. Regulation of Bone Mass, Osteoclast Function, and Ovariectomy-Induced Bone Loss by the Type 2 Cannabinoid Receptor Mice that lack CB2 did not differ from normal mice in peak bone mass, but after ovariectomy, a procedure that mimics the bone loss of menopause, wild-type mice lost more bone than the CB2-knockout mice. That same CB2-blocking compound protected against bone loss after ovariectomy, pointing toward cannabinoid receptor antagonists as possible treatments for osteoporosis.20PubMed Central. Cannabinoid receptors as target for treatment of osteoporosis: a tale of two therapies
Skin Health
The skin has its own functional endocannabinoid system that helps govern the balance between cell growth, differentiation, death, and immune responses in the skin and its appendages. The main physiological role appears to be keeping skin cell populations stable: controlling how fast keratinocytes, hair follicle cells, and sebocytes proliferate and how they mature.21PubMed Central. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities When that system goes out of balance, skin conditions from acne (overactive sebocytes) to dermatitis (overactive immune response) may follow. This is still a young area of research, but topical cannabinoid products are already being marketed with varying degrees of evidence behind them.
Reproduction and Early Development
CB1 and CB2 play a surprisingly precise role in the earliest stages of pregnancy. Endocannabinoid signaling is involved in preimplantation embryo development, the transport of the embryo through the fallopian tube, and the process by which an embryo attaches to the uterine wall.22PubMed Central. Aspects of endocannabinoid signaling in periimplantation biology Mouse experiments illustrate how critical the timing is. When researchers bred mice lacking CB1, CB2, or both, embryos from all knockout groups developed more slowly: on day three, roughly 84% of normal embryos had reached the eight-cell stage, compared with only about 24% of CB1-knockout embryos and around 42% of CB2-knockout embryos. These embryos were viable and eventually caught up, but the developmental delay shows that cannabinoid signaling sets the pace for early cell division.23Journal of Biological Chemistry. Dysregulated Cannabinoid Signaling Disrupts Uterine Receptivity for Embryo Implantation
The Rimonabant Lesson
The metabolic functions of CB1 made it an obvious drug target. If blocking CB1 could reduce appetite and improve fat and sugar metabolism, you might have a powerful obesity treatment. That was the logic behind rimonabant, a CB1 blocker that reached the European market in the mid-2000s. It worked: patients lost weight and showed improvements in metabolic markers. But because rimonabant crossed freely into the brain and shut down CB1 signaling there, it also caused anxiety, depression, and in some cases suicidal thoughts.24Current Topics in Medicinal Chemistry. Overcoming the psychiatric side effects of the cannabinoid CB1 receptor antagonists: Current approaches for therapeutics development The drug was pulled from the market, and the episode became a cautionary tale about the risks of broadly suppressing a receptor that does so many things across so many tissues.25PubMed. The psychiatric side-effects of rimonabant
The rimonabant failure did not kill interest in CB1 as a metabolic target. Instead, it redirected research toward compounds that cannot cross into the brain. These peripherally restricted CB1 blockers aim to capture the metabolic benefits, like reduced weight gain and improved glucose handling, without touching the central nervous system. In mice on a high-fat diet, one such compound inhibited weight gain and improved glucose utilization without producing the psychiatric effects seen with rimonabant.26PubMed Central. Peripherally Selective CB1 Receptor Antagonist Improves Symptoms of Metabolic Syndrome in Mice Other strategies being explored include neutral antagonists (which block the receptor without pushing it in the opposite direction) and antibody-based approaches.27PubMed. Cannabinoid Receptors in Metabolic Regulation and Diabetes
Allosteric Modulators and the Next Generation of Cannabinoid Drugs
Another avenue that has gained momentum is allosteric modulation. Instead of directly activating or blocking the receptor at its main binding site, allosteric modulators bind to a different spot on the receptor and tweak how it responds to whatever endocannabinoids are already present. The appeal is subtlety: an allosteric modulator can turn the volume up or down on the receptor’s natural signaling without replacing it entirely. This reduces the risk of desensitization, tolerance, and dependence that come with drugs that sit in the main binding site.28PubMed. Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery Allosteric modulators also tend to be more selective for one receptor type over the other, which could help separate therapeutic effects from side effects.
Adding another layer of complexity, CB2 does not always work alone. In cell studies, CB2 and a related receptor called GPR55 can physically link together, forming a paired unit that changes the signaling output of both receptors. When CB2 and GPR55 pair up, some signaling pathways get dampened while others get amplified.29PubMed Central. Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling This kind of receptor cross-talk means that the effect of a CB2-targeting drug can change depending on which other receptors are nearby in a given tissue, a complication that drug designers are only beginning to account for.
Genetic Variation in CB1 and What It Might Mean
People do not all carry identical versions of the genes encoding cannabinoid receptors, and some of those variations may have measurable effects on everyday experience. In one study, carriers of a particular variant (the C allele) in the gene for CB1, known as CNR1, scored higher on a standardized measure of subjective happiness and reported more positive mood responses after watching a feel-good film.30PLoS ONE. Genetic Variations in the Human Cannabinoid Receptor Gene Are Associated with Happiness That is a single study with a modest sample, so it is premature to call CNR1 a “happiness gene,” but it illustrates the principle that small differences in receptor function can ripple out into psychological traits.
On the clinical side, rare coding variants in CNR1 have been linked to increased pain sensitivity, particularly migraine, as well as sleep and memory difficulties, sometimes in combination with anxiety.31PLoS ONE. Rare genetic variants in the endocannabinoid system genes CNR1 and DAGLA are associated with neurological phenotypes in humans These findings are still being replicated and refined, but they suggest that part of the wide individual variation in pain thresholds, mood, and cannabis sensitivity may trace back to the receptor hardware people are born with.
How Old Is This System
The endocannabinoid system is not a recent evolutionary add-on. Genes encoding CB1-like receptors have been identified in fish, amphibians, and birds, indicating that they are present throughout vertebrates.32PubMed Central. The neurobiology and evolution of cannabinoid signalling The system appears to predate vertebrates altogether: a receptor that is an ancestor of both CB1 and CB2 has been found in the sea squirt Ciona intestinalis, a simple marine animal that belongs to the same broad branch of the animal kingdom as vertebrates but diverged from our lineage hundreds of millions of years ago. In the sea squirt, this receptor is already targeted to axons, suggesting that regulating nerve signaling was one of its original functions.33PubMed Central. The evolution and comparative neurobiology of endocannabinoid signalling
Insects, nematodes, and other protostomian invertebrates do not have CB1 or CB2 orthologs, which means the cannabinoid receptor system is likely restricted to the deuterostome branch of the animal family tree.32PubMed Central. The neurobiology and evolution of cannabinoid signalling That is a narrower distribution than many people assume. Cannabis plants produce compounds that happen to fit these receptors, but the receptors did not evolve because of cannabis. They evolved to respond to the body’s own endocannabinoids, and the plant molecules are, in evolutionary terms, accidental keys that happen to fit the lock.
Cannabinoid Receptors and Cancer Research
A growing area of preclinical work involves the role of cannabinoid receptors in cancer biology. In laboratory models of breast cancer bone metastasis, activating both CB1 and CB2 together produced toxic effects on an aggressive breast cancer cell line by increasing programmed cell death and suppressing a key pro-survival signaling pathway. The same receptor activation also inhibited cancer cell migration.34Scientific Reports. Activation of cannabinoid receptors in breast cancer cells improves osteoblast viability in cancer-bone interaction model while reducing breast cancer cell survival and migration These are cell-culture and animal findings, not clinical evidence in humans, and the gap between killing cancer cells in a dish and treating cancer in a patient is enormous. But the results add to a body of work suggesting that cannabinoid receptors influence tumor cell behavior in ways worth investigating further.